Suppliers / BrightGene Bio-Medical Technology

BrightGene Bio-Medical Technology

China 688166.SS 21 employees Updated 9 July 2026

BrightGene Bio-Medical Technology is an API manufacturer based in China. It holds 35 active US drug master files and 3 valid CEPs across a filed portfolio of 25 molecules.

35
active US DMFs
3
valid CEPs
1
registered plants
3
filings across 1 regulators

Registered plants

Site FDA FEI
Suzhou, China Not on file

What they file, and where

Molecule Regulators Docs
Everolimus EDQM, US FDA 3
Micafungin US FDA 3
Posaconazole US FDA 3
Dalbavancin US FDA 2
Entecavir EDQM, US FDA 2
Fidaxomicin US FDA 2
Fondaparinux US FDA 2
Oseltamivir EDQM, US FDA 2
Pimecrolimus US FDA 2
Saxagliptin US FDA 2
Show all 25 molecules on file
(21R)-Argatroban US FDA 1
Anidulafungin US FDA 1
Carboprost US FDA 1
Caspofungin US FDA 1
Eribulin US FDA 1
Exatecan US FDA 1
Ferric Carboxymaltose US FDA 1
Isavuconazonium US FDA 1
Lurbinectedin US FDA 1
Molnupiravir US FDA 1
Pemetrexed US FDA 1
Sirolimus US FDA 1
Sugammadex US FDA 1
Trabectedin US FDA 1
Voclosporin US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 3 None

Comparing suppliers?

Choose your molecules and target markets. BrightGene Bio-Medical Technology comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability